← Back to Clinical Trials
Recruiting NCT06646432

NCT06646432 Treatment of Gingival Recession With Tunnel Technique Using Connective Tissue Graft and Injectable Platelet Rich Fibrin

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06646432
Status Recruiting
Phase
Sponsor Suez Canal University
Condition Gingival Recession
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2024-11-01
Primary Completion 2025-06

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Tunnel with connective tissue graft and injectable platelet rich fibrinTunnel with connective tissue graft only

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2024-11-01 with a primary completion date of 2025-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Gingival recession is a common periodontal problem. Consequences include teeth sensitivity, poor esthetics and impaired oral hygiene access. Mild cases are managed by optimizing oral hygiene measures, correction of any causative factor such as faulty tooth brushing, improper dental restoration or denture clasp. Prescription of desensitization products such as specific tooth gels or mouth washes can manage the sensitivity problem. Deeper recession defects need to be addressed by surgical procedures. Coronally advanced flap with connective tissue graft is the gold standard procedure. However, it has some drawbacks due to the need for papillary incisions and vertical incisions in some cases. Within the era of minimally invasive periodontology, tunnel technique with connective tissue graft showed results comparable to coronally advanced flap with connective tissue graft but with some limitations. Addition of another agent may enhance the results of tunnel technique. Injectable platelet rich fibrin is known for its content of growth factors and effects on soft tissue healing. Aim: The study aim is to compare the surgical management of gingival recession with tunnel technique using connective tissue graft and injectable platelet rich fibrin to tunnel with connective graft without injectable platelet rich fibrin. Methodology: 30 patients with miller class I or II gingival recession will be enrolled. 15 in the test group (Tunnel+ CTG+ i-PRF) and 15 in control group (Tunnel+ CTG). Clinical evaluation at 6 months

Eligibility Criteria

Inclusion Criteria: * More than 21 years old * Systemically healthy * Presence of Miller class I/II gingival recession * Presence of identifiable CEJ Exclusion Criteria: * Smoking * Systemic disease that contraindicates surgical procedures. * Poor compliance with oral hygiene measures * Necrotizing gingival conditions * Ongoing active periodontitis

Contact & Investigator

Central Contact

Mohammed Abdel-aziz

✉ mohamed_naser@dent.suez.edu.eg

📞 00201118580817

Principal Investigator

Abdelnasser Elrefaey

STUDY CHAIR

Suez Canal University

Frequently Asked Questions

Who can join the NCT06646432 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Gingival Recession. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06646432 currently recruiting?

Yes, NCT06646432 is actively recruiting participants. Contact the research team at mohamed_naser@dent.suez.edu.eg for enrollment information.

Where is the NCT06646432 trial being conducted?

This trial is being conducted at Ismailia, Egypt.

Who is sponsoring the NCT06646432 clinical trial?

NCT06646432 is sponsored by Suez Canal University. The principal investigator is Abdelnasser Elrefaey at Suez Canal University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology